Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder66
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder22
Expert opinion on emerging drugs for lung chronic graft-versus-host disease20
Emerging drugs for the treatment of hepatocellular carcinoma19
Emerging drugs for hemophilia A: insights into phase II and III clinical trials17
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials14
Emerging drugs for the treatment of major depressive disorder13
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials13
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials12
Emerging therapeutics in Huntington’s disease12
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients11
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria11
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results10
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?10
Emerging drugs for the treatment of alopecia areata10
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials9
Emerging drugs for the treatment of myasthenia gravis9
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?8
A review of phase II and III drugs for the treatment and management of endometriosis8
Recent advances in immune-based approaches for the treatment of esophagogastric cancer7
FcRn inhibitors in the context of myasthenia gravis7
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer’s disease?7
Mitapivat: a step forward across different hemolytic diseases7
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion6
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder6
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma6
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?5
Emerging drugs for the treatment of postsurgical pain5
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’5
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials5
Current and emerging drug treatment strategies to tackle sickle cell anemia5
Emerging drugs in the treatment of chronic cough5
An update on emerging drugs for the treatment of hypercholesterolemia5
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis5
Emerging drugs for the treatment of inflammatory bowel disease5
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma4
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials4
Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials4
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia4
Emerging biological therapies for the treatment of malignant pleural mesothelioma4
Correction4
Emerging tyrosine kinase inhibitors for head and neck cancer4
Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency4
Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update4
Systemic mastocytosis: 2023 update on diagnosis and management in adults4
Emerging antiviral therapies and drugs for the treatment of influenza4
New drugs targeting calcitonin gene-related peptide for the management of migraines4
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials3
An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia3
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity3
How will tovorafenib change our treatment of pediatric low-grade glioma?3
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials3
Designing phase II clinical trials in Friedreich ataxia3
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review3
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa3
Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials3
Emerging oral drug options for ulcerative colitis3
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials3
Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer’s disease3
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies3
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma3
Emerging drugs for the treatment of glaucoma: a review of phase II & III trials3
Emerging medicines to improve the basic defect in cystic fibrosis3
Correction3
Emerging drugs for the treatment of bladder storage dysfunction2
Emerging drugs for the treatment of adrenocortical carcinoma2
Emerging biological treatments for asthma2
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia2
Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle2
New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma2
Emerging therapies for dry eye disease2
Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera2
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia2
Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update2
0.14334297180176